<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147420</url>
  </required_header>
  <id_info>
    <org_study_id>GN 10</org_study_id>
    <nct_id>NCT00147420</nct_id>
  </id_info>
  <brief_title>RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet</brief_title>
  <official_title>RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Global Network for Women's and Children's Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Network for Women's and Children's Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fogarty International Center of the National Institute of Health</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Bureau Tibet Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>One Heart Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Global Network for Women's and Children's Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous research has confirmed that hemorrhage is among the most commonly encountered&#xD;
      pregnancy complications in the Tibet Autonomous Region (TAR). This trial will test the&#xD;
      effectiveness of a traditional Tibetan drug (Zhi Byed 11) vs. misoprostol to prevent&#xD;
      postpartum hemorrhage (PPH) among women delivering vaginally in three hospitals in Lhasa,&#xD;
      TAR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-partum hemorrhage (PPH) is one of the main direct causes of maternal mortality,&#xD;
      particularly in rural areas with low access to skilled providers, blood banks, and surgical&#xD;
      facilities. In addition to the mortality, PPH also accounts for a great number of&#xD;
      morbidities, including anemia, renal and pulmonary problems, fatigue, and decreased&#xD;
      resistance to infection, all major health problems affecting women in the TAR. Clinical&#xD;
      research is rare in the Tibetan Autonomous Region (TAR) of the People's Republic of China.&#xD;
      This trial will estimate the effect of prophylactic oral ZB 11 administered at the beginning&#xD;
      of the second stage of labor versus prophylactic oral misoprostol, administered in the third&#xD;
      stage of labor, in reducing the incidence of postpartum hemorrhage (defined as a measured&#xD;
      blood loss of &gt; 500 cc).&#xD;
&#xD;
      An observational postpartum blood measurement study was conducted. This included data&#xD;
      collection on deliveries in three TAR hospital in Lhasa, piloting of consent forms and data&#xD;
      collection instruments, and training in the use of a plastic drape for the measurement of&#xD;
      postpartum blood loss.&#xD;
&#xD;
      This randomized, double masked trial will test the hypothesis that misoprostol is more&#xD;
      effective than ZB11 in reducing the frequency of postpartum hemorrhage (defined as either a&#xD;
      measured blood loss of &gt; 500cc or administration of open label uterotonics within the one&#xD;
      hour observation period after delivery).&#xD;
&#xD;
      An original sample of 848 women was increased and 967 consenting women were randomized (1:1)&#xD;
      to a ZB11 or misoprostol arm. Since ZB 11 and misoprostol must be administered at different&#xD;
      times, participants will receive either active ZB 11 or corresponding placebo at full&#xD;
      dilation and active misoprostol or corresponding placebo immediately following the birth of&#xD;
      the baby. The effectiveness of the study drug will be estimated by the postpartum blood loss&#xD;
      that will be measured on all enrolled women with a blood collection drape.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postpartum hemorrhage</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal death</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated average blood loss of women during birth</measure>
  </secondary_outcome>
  <enrollment>848</enrollment>
  <condition>Hemorrhage</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zhi Byed 11</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion and Exclusion Criteria&#xD;
&#xD;
        Adult, pregnant women who satisfy all the following criteria may be enrolled in the study.&#xD;
        Pregnant women:&#xD;
&#xD;
          -  who are delivering during the study period at one of the three hospitals&#xD;
&#xD;
          -  who are 18 years of age or older at the time of delivery&#xD;
&#xD;
          -  who are 28 weeks or more pregnant&#xD;
&#xD;
          -  who are likely to have a normal vaginal delivery&#xD;
&#xD;
          -  with singleton intrauterine pregnancy with vertex presentation either in early labor&#xD;
             or in anticipation of induction of labor, and&#xD;
&#xD;
          -  whose fetus is alive (has a heart rate &gt;100bpm) at the time of screening&#xD;
&#xD;
          -  who are able to give informed consent.&#xD;
&#xD;
        Any of the following criteria will exclude a woman from study participation:&#xD;
&#xD;
          -  pre-term labor (&lt;28 weeks)&#xD;
&#xD;
          -  previous or planned cesarean delivery&#xD;
&#xD;
          -  current multiple gestations&#xD;
&#xD;
          -  active hemorrhaging&#xD;
&#xD;
          -  severe anemia (Hgh &lt;7)&#xD;
&#xD;
          -  hypertension (persistent BP&gt;140/90 or greater OR hypertension requiring treatment)&#xD;
             [this criteria was omitted mid-study]&#xD;
&#xD;
          -  maternal history of bleeding disorders&#xD;
&#xD;
          -  known allergies to any medications (severe chronic allergic conditions)&#xD;
&#xD;
          -  body temperature greater than 38ÂºC&#xD;
&#xD;
          -  asthma (asthma requiring treatment)&#xD;
&#xD;
          -  mental disability&#xD;
&#xD;
          -  unable to focus on consent process due to imminent delivery&#xD;
&#xD;
        To be eligible for participation as a care provider, the participant must satisfy the&#xD;
        following criteria:&#xD;
&#xD;
          -  obstetrical care provider to pregnant woman in the study&#xD;
&#xD;
          -  at least 18 years of age&#xD;
&#xD;
          -  must be a physician or nurse midwife&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Varner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lhasa Maternal-Child Health (MCH) Hospital</name>
      <address>
        <city>Lhasa</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lhasa Municipal Hospital</name>
      <address>
        <city>Lhasa</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mentzikhang Traditional Tibetan Medicine and Astrology Hospital</name>
      <address>
        <city>Lhasa</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://gn.rti.org</url>
    <description>Global Network for Women and Children's Health Research</description>
  </link>
  <link>
    <url>http://uuhsc.utah.edu/oneheart/index.html</url>
    <description>Health Education and Research in Tibet</description>
  </link>
  <link>
    <url>http://www.rti.org</url>
    <description>Research Triangle Institute International</description>
  </link>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tibet</keyword>
  <keyword>Third Stage Labor</keyword>
  <keyword>Post Partum Hemorrhage</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Zhi Byed 11</keyword>
  <keyword>Global Network</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

